Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brexpiprazole for agitation in Alzheimer's dementia
NCT03548584Phase 3Completed
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization
- Start
- May 2018
- Primary completion
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of brexpiprazole orally disintegrating tablet in agitation, sponsored by Otsuka Pharmaceutical Development & Commercialization. Started May 2018; status: completed.
02
Drugs
brexpiprazole orally disintegrating tablet
03
Conditions
agitation
Beyond the preview
Go deeper on NCT03548584.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03548584.